Christopher Oermann
Overview
Explore the profile of Christopher Oermann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
130
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Duehlmeyer S, Meier E, Oermann C
Pediatr Pulmonol
. 2024 Oct;
60(1):e27363.
PMID: 39451040
No abstract available.
2.
Tam-Williams J, Oermann C, Duehlmeyer S
Pediatr Pulmonol
. 2024 Aug;
59(12):3774-3776.
PMID: 39150097
No abstract available.
3.
Elson E, Oermann C, Duehlmeyer S, Bledsoe S
Am J Health Syst Pharm
. 2020 May;
77(13):1005-1006.
PMID: 32369111
No abstract available.
4.
Ren C, Morgan R, Oermann C, Resnick H, Brady C, Campbell A, et al.
Ann Am Thorac Soc
. 2018 Jan;
15(3):271-280.
PMID: 29342367
Rationale: Cystic fibrosis (CF) transmembrane conductance regulator (CFTR) modulators are a new class of medications targeting the underlying defect in CF. Ivacaftor (IVA) and IVA combined with lumacaftor (LUM; IVA/LUM)...
5.
Retsch-Bogart G, Burns J, Otto K, Liou T, McCoy K, Oermann C, et al.
Pediatr Pulmonol
. 2007 Nov;
43(1):47-58.
PMID: 18041081
Background: Aztreonam lysine for inhalation (AZLI) is being developed for treatment of CF patients with Pseudomonas aeruginosa airway infection. Methods: This double-blind, randomized, placebo-controlled Phase 2 study evaluated the safety,...
6.
Gibson R, Retsch-Bogart G, Oermann C, Milla C, Pilewski J, Daines C, et al.
Pediatr Pulmonol
. 2006 May;
41(7):656-65.
PMID: 16703579
Background: Aztreonam lysinate for inhalation (AI) is a novel monobactam formulation being investigated for pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF). Methods: Pre-clinical studies investigated the pre-...
7.
Buyse I, McCarthy S, Lurix P, Pace R, Vo D, Bartlett G, et al.
Genet Med
. 2004 Sep;
6(5):426-30.
PMID: 15371908
Purpose: We developed a 51-mutation extended cystic fibrosis (CF) panel that incorporates the 25 previously recommended CFTR mutations, plus 26 additional mutations including 3199del6, which was associated with I148T. Methods:...